Purple Biotech PPBT 深 滬
等待開盤 07-18 09:30:00 美东时间
2.53
+0.020
+0.80%
華盛通- 最 高2.60
- 今 開2.50
- 成交量 1.03万股
- 最 低 2.4606
- 昨 收 2.51
- 總市值 669.99万
- 52周最高 13.95
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 2.00
- 委 比 72.41%
- 總股本 264.82万
- 歷史最高 1390.00
- 量 比 0.81
- 振 幅 5.55%
- 歷史最低 2.10
- 每 手 1
- 風險率 2.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
<p>REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) in Lisbon, Po...
06-23 11:00
Purple Biotech Initiated Phase 2 Study Evaluating NT219 In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 (Insulin Receptor Substrates 1 and 2) and STAT3 (Signal Transducer and Activator of Transcription 3). NT219 induces the
06-17 19:05
Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Purple Biotech Ltd. has initiated a Phase 2 clinical study to evaluate NT219, a novel small molecule targeting IRS1/2 and STAT3 pathways, in combination with pembrolizumab or cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study, led by Dr. Antonio Jimeno at the University of Colorado, is structured into two single-arm cohorts with potential expansion, aiming to assess efficacy and...
06-17 11:00
Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
Purple Biotech Ltd. announced its participation in the EACR 2025 Congress with a poster presentation on its novel CAPTN-3 tri-specific antibody platform, designed to activate T cells and NK cells for enhanced anti-tumor immune response. The presentation, titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers," will be delivered by Dr. Hadas Reuveni on June 17, 2025, in Lisbon. The abstract (EACR25-1964) highlight...
06-04 11:00
Purple Biotech GAAP EPADS of -$0.17
Purple Biotech press release (NASDAQ:PPBT): Q1 GAAP EPADS of -$0.17. More on Purple Biotech Seeking Alpha’s Quant Rating on Purple Biotech Historical earnings data for Purple Biotech Financial informa...
05-21 19:14
Purple Biotech Q1 EPS $(0.17) Misses $(0.06) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.06) by 183.33 percent. This is a 93.93 percent increase over losses of $(2.80) per share from
05-21 19:14
Purple Biotech Appoints New CFO Amid Strategic Growth
The latest announcement is out from Purple Biotech ( ($PPBT) ). On May 12, 2025...
05-12 19:58
Purple Biotech names Shai Lankry as CFO
Purple Biotech (NASDAQ:PPBT) said it has appointed Shai Lankry as its finance chief. Before joining the company, Lankry supported several companies as a strategic fractional chief financial officer t...
05-12 19:52
Purple Biotech Announces Promising NT219 Data for Cancer Treatment
Purple Biotech ( ($PPBT) ) has shared an announcement. On April 28, 2025, Purpl...
04-28 21:44
Purple Biotech Announces Key Decisions from April 2025 Shareholder Meeting
An update from Purple Biotech ( ($PPBT) ) is now available. On April 22, 2025, ...
04-23 04:57
